XML 37 R21.htm IDEA: XBRL DOCUMENT
v3.24.4

GOODWILL AND OTHER INTANGIBLE ASSETS | 12 Months Ended
--- | ---
Oct. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2023 and 2024:
| Life Sciences and Applied Markets |  | Diagnostics and Genomics |  | Agilent CrossLab |  | Total
| (in millions)
Goodwill as of October 31, 2022 | $ | 1,575 |  |  | $ | 2,121 |  |  | $ | 256 |  |  | $ | 3,952 |
Foreign currency translation impact | 4 |  |  | 1 |  |  | 1 |  |  | 6 |
Goodwill arising from acquisitions and adjustments | — |  |  | 15 |  |  | — |  |  | 15 |
Goodwill adjustment related to divestiture of business | — |  |  | (13) |  |  | $ | — |  |  | (13) |
Goodwill as of October 31, 2023 | $ | 1,579 |  |  | $ | 2,124 |  |  | $ | 257 |  |  | $ | 3,960 |
Foreign currency translation impact | 4 |  |  | (15) |  |  | 2 |  |  | (9) |
Goodwill arising from acquisitions and adjustments | — |  |  | 526 |  |  | — |  |  | 526 |
Goodwill as of October 31, 2024 | $ | 1,583 |  |  | $ | 2,635 |  |  | $ | 259 |  |  | $ | 4,477 |
In the first quarter of fiscal year 2024, we reorganized our operating segments and moved our cell analysis business from our life sciences and applied markets business segment to our diagnostics and genomics business segment. As a result, we reassigned approximately $168 million of goodwill from our life sciences and applied markets business segment to our diagnostics and genomics business segment using the relative fair value allocation approach. Goodwill balances as of October 31, 2022 and 2023, have been recast to conform to this new presentation. As a result of the reorganization, there was no change to our reporting units. In addition, we performed a goodwill impairment test, and the results of the analysis indicated that the fair values for all three of our reporting units were in excess of their carrying values by substantial amounts; therefore, no impairment was indicated. In connection with the divestiture of our Resolution Bioscience business in the fourth quarter of fiscal year 2023, we received $50 million in cash and recorded a gain on the divestiture of $43 million in other income (expense), net in the consolidated statement of operations which included an adjustment to goodwill of $13 million in our diagnostics and genomics segment. We used the relative fair value approach in determining the adjustment to goodwill. As of September 30, 2024, our annual impairment test date, we assessed goodwill for our reporting units, and no impairment of goodwill was indicated. There was no impairment of goodwill in fiscal years 2023 and 2022. The component parts of other intangible assets at October 31, 2023 and 2024 are shown in the table below:
| Other Intangible Assets
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Book Value
| (in millions)
As of October 31, 2023: |  |  |  |  |
Purchased technology | $ | 1,467 |  |  | $ | 1,093 |  |  | $ | 374 |
Trademark/Trade name | 196 |  |  | 163 |  |  | 33 |
Customer relationships | 149 |  |  | 112 |  |  | 37 |
Third-party technology and licenses | 34 |  |  | 13 |  |  | 21 |
Total amortizable intangible assets | $ | 1,846 |  |  | $ | 1,381 |  |  | $ | 465 |
In-Process R&D | 10 |  |  | — |  |  | 10 |
Total | $ | 1,856 |  |  | $ | 1,381 |  |  | $ | 475 |
As of October 31, 2024: |  |  |  |  |
Purchased technology | $ | 1,484 |  |  | $ | 1,169 |  |  | $ | 315 |
Backlog | 9 |  |  | — |  |  | 9 |
Trademark/Trade name | 199 |  |  | 174 |  |  | 25 |
Customer relationships | 291 |  |  | 107 |  |  | 184 |
Third-party technology and licenses | 33 |  |  | 19 |  |  | 14 |
Total amortizable intangible assets | $ | 2,016 |  |  | $ | 1,469 |  |  | $ | 547 |
In-Process R&D | — |  |  | — |  |  | — |
Total | $ | 2,016 |  |  | $ | 1,469 |  |  | $ | 547 |
In fiscal year 2024, we recorded additions of $526 million to goodwill in our diagnostics and genomics segment related to the BIOVECTRA acquisition. In addition, we recorded $188 million to other intangible assets related to BIOVECTRA and another acquisition. As of October 31, 2024, gross carrying amount of customer relationships includes approximately $165 million related to BIOVECTRA which was valued using the multi-period excess earnings method under the income approach which values the customer relationships by discounting the direct cash flow expected to be generated by the customers. During fiscal year 2024, we reclassified $4 million of in-process research and development intangible assets to purchased technology upon the completion of a project. During fiscal year 2024, other intangible assets in total decreased $5 million due to the impact of foreign currency translation. During 2024, we also wrote-off the gross carrying amounts of $18 million and the related accumulated amortization of fully amortized intangible assets which were no longer being used. In fiscal year 2023, we acquired two businesses for a total purchase price of $51 million. As a result, we recorded additions of $15 million to goodwill and $50 million to other intangible assets in our diagnostics and genomics and life sciences and applied markets segments primarily related to these two acquisitions. During fiscal year 2023, other intangible assets in total increased $2 million due to the impact of foreign currency translation. During 2023, we also wrote-off the gross carrying amounts of $7 million and the related accumulated amortization of fully amortized intangible assets which were no longer being used. In general, for United States federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible. During fiscal year 2024, we recorded an impairment of in-process research and development of $6 million in research and development in the consolidated statement of operations related to a project in our life sciences and applied markets segment. There were no impairments of indefinite-lived intangible assets during fiscal years 2023 and 2022. During fiscal years 2024 and 2022, there were no impairments of finite-lived intangible assets recorded. During the third quarter of fiscal year 2023, we recorded an impairment of finite-lived intangible assets of $258 million related to the exit of our Resolution Bioscience business in our diagnostics and genomics segment. Of the $258 million, $249 million was recorded in cost of sales and $9 million was recorded in selling, general and administrative expenses on our consolidated statement of operations. Amortization expense of intangible assets was $105 million in 2024, $140 million in 2023, and $192 million in 2022. Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense: |
| (in millions)
2025 | $ | 104 |
2026 | $ | 75 |
2027 | $ | 72 |
2028 | $ | 65 |
2029 | $ | 61 |
Thereafter | $ | 170 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration